The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Amryt Pharmaceuticals DACEU/1/13/851/006

Main Information

Trade NameLojuxta
Active SubstancesLomitapide mesylate
Dosage FormCapsule, hard
Licence HolderAmryt Pharmaceuticals DAC
Licence NumberEU/1/13/851/006

Group Information

ATC CodeC10AX Other lipid modifying agents
C10AX12 lomitapide


License statusAuthorised
Licence Issued18/02/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back